Stockscreener 앱 받기
2.18
2.24%
-0.05
시간 외 거래:
2.11
-0.07
-3.21%
전일 마감가:
$2.23
열려 있는:
$2.23
하루 거래량:
61,480
Relative Volume:
0.53
시가총액:
$5.56M
수익:
-
순이익/손실:
$-4.74M
주가수익비율:
-2.9067
EPS:
-0.75
순현금흐름:
$-3.46M
1주 성능:
-9.17%
1개월 성능:
-9.54%
6개월 성능:
-10.18%
1년 성능:
-64.26%
1일 변동 폭
$2.15
$2.31
1주일 범위
$2.15
$2.49
52주 변동 폭
$1.965
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
명칭
Lipella Pharmaceuticals Inc
전화
412-901-0315
주소
400 N LEXINGTON ST, PITTSBURGH
LIPO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
2.18 | 6.12M | 0 | -4.74M | -3.46M | -0.75 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Lipella Pharmaceuticals Inc 주식(LIPO)의 최신 뉴스
Lipella Pharmaceuticals Faces Nasdaq Compliance Challenge - TipRanks
LIPO: Lipella Pharmaceuticals Reports Promising Phase 2a Trial Results for LP-310 | LIPO Stock News - GuruFocus
Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data - TipRanks
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 - GlobeNewswire
Breakthrough Phase 2a Data: New LP-310 Treatment Cuts Oral Lichen Planus Pain by 65%, Exceeds Endpoints - Stock Titan
Analytical Overview: Lipella Pharmaceuticals Inc (LIPO)’s Ratios Tell a Financial Story - DWinneX
Lipella Pharmaceuticals Abstract on Oral Lichen Planus - GlobeNewswire
Clinical Data: New Treatment Breakthrough for Oral Lichen PlanusPhase 2a Trial Shows Remarkable Improvement - Stock Titan
LIPO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
LIPO stock’s current quarter earnings estimates: What analysts predict? - uspostnews.com
Lipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus - Reuters
Lipella Pharmaceuticals announces results from second cohort of LP-310 trial - TipRanks
Lipella Reports Positive Phase 2a Results from Second - GlobeNewswire
Clinical Trial Breakthrough: New Oral Lichen Planus Treatment Shows 65% Pain Reduction, Multiple Endpoint Success - Stock Titan
Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis - MarketBeat
Lipella Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Canada
Lipella Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Lipella Pharmaceuticals expands preferred stock class - Investing.com Australia
Lipella Pharmaceuticals stock hits 52-week low at $2 By Investing.com - Investing.com Canada
Lipella Pharmaceuticals expands preferred stock class By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals stock hits 52-week low at $2 - Investing.com
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus - The Manila Times
Clinical Trial Success: Lipella's Novel OLP Treatment Shows Encouraging Results in Phase 2a Study - Stock Titan
Virtu Financial LLC Acquires Shares of 13,310 Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast - The Globe and Mail
Clinical Trial Success: Lipella's 40-Year Veteran Shares Breakthrough Journey in Exclusive Interview - Stock Titan
Tariffs and Tech Troubles Weigh on Markets - The Globe and Mail
Lipella Pharmaceuticals Inc. (LIPO) reports earnings - Quartz
LIPELLA PHARMACEUTICALS INC. SEC 10-K Report - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Spartan Capital Securities, LLC Proudly Serves as the Sole Agent in Lipella Pharmaceuticals Inc. - Ukraine Business Journal
Lipella Pharmaceuticals stock hits 52-week low at $2.21 - Investing.com Australia
Spartan Capital Securities, LLC Announces Key February Transactions - The Manila Times
Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewswire Inc.
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement - Yahoo Finance
Lipella Pharmaceuticals (LIPO) Expected to Announce Earnings on Tuesday - Defense World
FDA approves Lipella's oral treatment access program - MSN
Lipella Pharmaceuticals modifies agreement with Spartan Capital By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals modifies agreement with Spartan Capital - Investing.com
With New Data, Lipella Plots 2025 Milestones For Oral Rinse Tacrolimus - News & Insights
Analyzing Lipella Pharmaceuticals (NASDAQ:LIPO) and IDEAYA Biosciences (NASDAQ:IDYA) - Defense World
Lipella Pharmaceuticals Gains Buy Rating from Jason McCarthy Following Positive Phase 2a Results for LP-310 - TipRanks
3 Penny Stocks to Watch Now, 2/13/25 - TipRanks
Lipella Pharmaceuticals Announces Positive Phase 2a Results for LP-310 in Oral Lichen Planus Treatment - Defense World
Biotech Rips On Topline Analysis - The Globe and Mail
Lipella Pharmaceuticals Inc (LIPO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):